Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISA104 in Chronic Hepatitis B
NCT05841095Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ISA104 in Chronic Hepatitis B (CHB), sponsored by Erasmus MC. Started Aug 2023; status: active, not recruiting.
02
Drugs
ISA104
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05841095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841095.